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TABLE 1. PATIENT CHARACTERISTICS OF 
PEDIATRIC COHORT (<15 years)
_____________________________________________
Adults 2303 (88,7%)
Children on ART 293 (11,3%)
< 5 years 81 (28%)
5 to 14 yr 212 (72%)
Mean age 7.3
Female (%) 52 %
Median time ART (IQR) 16.9 months (10-23) (397 patient years FU)
______________________________________________
Baseline CD4 %
< 5 years (IQR) 15 % (10.5-19) 
5-14 years (IQR) 12 % (9-16) 
in absolute count 292 (179-404)
______________________________________________
Baseline SGPT 25.3 (19-35)
Baseline Hb 11.1 (10.4-11.8)
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BACKGROUND AND METHODS
MSF started in 2002 in Kigali with a comprehensive care for PLWHA and in 2003 with 
HAART. From the start we opted for a family approach, hence the large cohort of children on 
treatment.
We describe the treatment outcomes in children (< 15 years of age) and assess the safety of 
HAART. 
Data were routinely collected using a monitoring software (Access®). Treatment and safety 
outcomes were analysed by Excel® and SPSS®.
PATIENT CHARACTERISTICS
As of mid July 2006,  2596 patients were initiated on ARV of whom 7% have died or are lost 
to follow-up. 11,3 % (n=293) of our active cohort constitute of children. More than a quarter 
are younger than 5 years. Half are female (compared to 70% for the adult cohort) and two 
thirds (67%) are more than 1 year on treatment. Inclusion criteria for ART are based on old 
and new WHO guidelines (2003 and African region version 2005). 
Distribution of WHO stages 1, 2, 3 and 4 (new classification of 2005) at start of ARV are 
depicted in Fig.1. Main reason for entering stage 2 are dermatological manifestations followed 
by recurrent respiratory tract infections. In stage 3, children presented mainly with persistent 
diarrhoea, persistent fever, moderate malnutrition and/or oral candidiosis. Seven TB cases 
were recorded.
The majority (n=260,89%) started on d4T/3TC/NVP in line with WHO and MSF 
recommendations (see fig. 2). Once able to swallow tablets (from 2 to 3 years onwards), fixed 
dose combinations were prescribed based on a simplified dosing table with 4 weight 
categories. No quarters were used, only whole or half tablets (table 2).
TABLE 4. Side Effects
Livertoxicity (PACTG 1994)
• grade I (moderate: 50-100) 42 patients (16%)
• grade I (severe: 100-200) 14 patients (5%)
switch to EFV 4 patients
• grade II 7 patients (2,5%)
switch to EFV 3 patients
• grade III/IV 1 patient
SGPT follow-up (> 3 months)
Mean (IQR) 28 (20-40)
______________________________________________
Skin reactions 
with switch to EFV 11 patients (3%)
Peripheral neuropathy 0
Lactic acidosis 0       
TREATMENT CHARACTERISTICS AND OUTCOME
Overall treatment outcomes in July 2006 were: 261 (89%) alive and followed, 7 died and 
19 transferred out. Only 2% was lost to follow-up (see Table 3). 
After 5 months, 85% increased their weight. The ones not gaining had a mean loss of 1 kg. 
Haemoglobin levels raised with a mean of 1,5mg/dl to 12,6. 
Mean CD4% increases can be seen in Figure 3. Viral loads were routinely performed after 
1 year treatment (mean time 19 months, 101 results available). Eighty eight percent had 
less than 400 copies while only 8% were above > 5000 copies.
CONCLUSION
Our results show that it is feasible to initiate HAART in a large group of children in urban 
health centres. Side effects due to HAART are less common in children than in adults and none 
was life threatening. Follow-up with liver function tests may not be necessary since all 
treatment changes were in patients with symptomatic disease. Rural health centres starting 
access to HAART might consider focussing on children instead of adults given the fewer side 
effects (with less biochemical follow-up needed) and given the better response to treatment in 
terms of morbidity and mortality.
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Fig 2: Regimen at start HAART
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Fig 1: WHO stage (at start HAART)
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Fig 3a: CD4% evolution (< 5 years of age)
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Fig 3b: CD4 evolution (>= 5 to 14 yrs)
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TABLE 2. Viral loads (n=101)
< 40 copies 81 (80%) 
< 400 copies 89 (88%) 
> 400 copies 12 (12%)
> 5000 c. 8 (8%)
SAFETY
Liver function tests were performed at baseline, 2, 4, 8 weeks and then every 6 months and on 
clinical grounds. Severe hepatic abnormalities (grade 2-4 and symptomatic grade 1) appeared in 
12 cases (4,5%). Median time of onset was 43 days (IQR 30-122) with two thirds presenting 
before 2 months. Seven symptomatic (fatigue, nausea, fever, jaundice, RUQ pain and/or
hepatomegaly) children changed to EFV. Four of the eight patients with grade 2-3 levels 
continued NVP with spontaneous recovery.
Another 11 (4%) switched to EFV because of skin manifestations (allergy/dermatitis). Median 
time of onset was 24 days (82% within 1 month) and none had ALAT levels > 2,5 UNL.
Five changed to EFV due to start TB treatment.
n=208 n=141 n=88               n=60      n=38
< 10 kg Syrups
10 to 13 kg Triviro 30 ½ tab bid
Triviro 30 ½ tab bid + NVP ½ tab od
Triviro 40 ½ tab bid + NVP ½ tab od
21 to 30 kg Triviro 30 1 tab bid
14 to 17 kg
18 to 20 kg
Table 2: dosing scheme (> 14 d.)
TABLE 3. Treatment OUTCOMES
Mortality 7 patients (2,4%) 
Transfer out 19 patients (6,5%) 
Lost to follow-up 6 patients (2%)
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